Simvastatin Treatment Upregulates Anti-Fibrotic Bone Morphogenetic Protein-7 Expression at Rat Cardiac Allograft Rejection

Background: Bone morphogenetic protein (BMP)-7 mediates ischemic tolerance and anti-fibrotic effects in various organs such as kidney and heart. Recently, reno- and podocyte-protective effects of a potent HMG-CoA reductase inhibitor, pitavastatin, were accompanied by BMP-7 upregulation. Methods: Her...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Pharmacology 2016-01, Vol.98 (5-6), p.204-208
Hauptverfasser:	Holmström, Emil J., Lemström, Karl B., Tuuminen, Raimo
Format:	Artikel
Sprache:	eng
Schlagworte:	Allografts - drug effects Allografts - metabolism Animals Bone Morphogenetic Protein 7 - biosynthesis Bone morphogenetic proteins Cardiovascular diseases Development and progression Drug therapy Gene Expression Regulation Genetic aspects Genetic regulation Graft Rejection - metabolism Graft Rejection - prevention & control Health aspects Heart Transplantation - adverse effects Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use Male Patient outcomes Rats Rats, Wistar Short Communications Simvastatin Simvastatin - pharmacology Simvastatin - therapeutic use Up-Regulation - drug effects Up-Regulation - physiology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!